Open AccessVEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications
Author(s) -
Nicholas D. Camarda,
Richard Travers,
Vicky Yang,
Cheryl A. London,
Iris Z. Jaffe
Publication year - 2022
Publication title -
current oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.595
H-Index - 60
eISSN - 1534-6269
pISSN - 1523-3790
DOI - 10.1007/s11912-022-01224-0
Subject(s) - medicine , pharmacology , vegf receptors , oncology
While vascular endothelial growth factor receptor inhibitors (VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a majority of patients. This side effect is often dose limiting and increases cardiovascular mortality in cancer survivors. This review summarizes recent advances in our understanding of the molecular mechanisms and clinical findings that impact management of VEGFRi-induced hypertension.